Cadonilimab Combination With Chemotherapy With or Without AK117 in Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorAkeso
About this trial
This trial is a Phase II study. All patients are resectable Gastric or Gastroesophageal Junction Adenocarcinoma, Eastern Cooperative Oncology Group (ECOG) performance status 0-1.The purpose of this study is to evaluate the efficacy and safety of cadonilimab combined with chemotherapy with or without AK117 neoadjuvantin treatment of resectable Gastric or Gastroesophageal Junction Adenocarcinoma.
Eligibility criteria
Qualifiers
Be able and willing to provide written informed consent.
18 to 75 years old.
Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Has a histologically confirmed diagnosis of Gastric or Gastroesophageal Junction Adenocarcinoma(G/GEJ).
Disqualifiers
Are there suspected metastases or locally advanced, unresectable disease, regardless of disease stage.
Is currently participating in a study of an investigational agent or using an investigational device.
Has undergone major surgery within 30 days of Study Day 1.
Has an active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs).
Trial design
Treatments tested in this trial
- Cadonilimab
- AK117
- Oxaliplatin
- Tegafur-gimeracil-oteracil potassium
- Docetaxel
- 5-Fluorouracil
Treatment groups
90 Participants
are divided into 4 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov